Reker, Ashlie N.

AbstractThe corticostriatal circuitry and its glutamate‐γ‐aminobuturic acid (GABA) interactions play an essential role in regulating neuronal excitability during reward‐seeking behavior. However, the contribution of GABAergic interneurons in the corticostriatal circuitry remains unclear. To investigate the role of GABAergic interneurons, we focused on parvalbumin‐expressing fast‐spiking interneurons (Pv‐FSI) in the corticostriatal circuitry using the designer receptors exclusively activated by designer drugs approach in a Pv‐Cre mouse model. We hypothesize that Pv‐FSI activation elicits changes in cortical glutamate levels and reward‐seeking behaviors. To determine molecular and behavioral effects of Pv‐FSI, we performed microdialysis and operant conditioning tasks for sucrose and alcohol rewards. In addition, we also examined how alcohol reward itself affects Pv‐FSI functioning. Interestingly, our microdialysis results demonstrate that alcohol exposure inhibits Pv‐FSI functioning in the medial prefrontal cortex (mPFC) and this consequently can regulate glutamate levels downstream in the nucleus accumbens. For sucrose reward‐seeking behaviors, Pv‐FSI activation in the mPFC increases sucrose self‐administration whereas it does not promote alcohol seeking. For alcohol rewards, however, Pv‐FSI activation in the mPFC results in increased compulsive head entry in operant chambers during devaluation procedures. Overall, our results suggest that not only do Pv‐FSI contribute to changes in the cortical microcircuit and reward‐seeking behaviors but also that alcohol affects Pv‐FSI neurotransmission. Therefore, Pv‐FSI has prompted interest in their role in maintaining a balance in neuronal excitation/inhibition and in regulating reward‐seeking processes such as compulsivity, all of which are important factors for excessive alcohol seeking. image

AbstractAcamprosate is an FDA‐approved medication for the treatment of alcoholism that is unfortunately only effective in certain patients. Although acamprosate is known to stabilize the hyper‐glutamatergic state in alcoholism, pharmacological mechanisms of action in brain tissue remains unknown. To investigate the mechanism of acamprosate efficacy, the authors employ a pharmacoproteomics approach using an animal model of alcoholism, type 1 equilibrative nucleoside transporter (ENT1) null mice. The results demonstrate that acamprosate treatment significantly decreased both ethanol drinking and preference in ENT1 null mice compared to that of wild‐type mice. Then, to elucidate acamprosate efficacy mechanism in ENT1 null mice, the authors utilize label‐free quantification proteomics comparing both genotype and acamprosate treatment effects in the nucleus accumbens (NAc). A total of 1040 protein expression changes are identified in the NAc among 3634 total proteins detected. The proteomics and Western blot result demonstrate that acamprosate treatment decreased EAAT expression implicating stabilization of the hyper‐glutamatergic condition in ENT1 null mice. Pathway analysis suggests that acamprosate treatment in ENT1 null mice seems to rescue glutamate toxicity through restoring of RTN4 and NF‐κB medicated neuroimmune signaling compared to wild‐type mice. Overall, pharmacoproteomics approaches suggest that neuroimmune restoration is a potential efficacy mechanism in the acamprosate treatment of certain sub‐populations of alcohol dependent subjects.